Labenz Joachim, Borkenstein Daniela-Patricia, Heil Franz Josef, Madisch Ahmed, Tappe Ulrich, Schmidt Harald, Terjung Birgit, Klymiuk Ingeborg, Horvath Angela, Gross Manfred, Stadlbauer Vanessa
Department of Internal Medicine, Diakonie Klinikum Jung-Stilling, Siegen, Germany.
Praxis Dr. Heil und Dr. Müller, Andernach, Germany.
Front Oncol. 2023 Jan 9;12:1078315. doi: 10.3389/fonc.2022.1078315. eCollection 2022.
Even after decades of research and pharmaceutical development, cancer is still one of the most common causes of death in the western population and the management of cancer will remain a major challenge of medical research. One of the most common types of cancer is colorectal cancer (CRC). Prevention by detection of early-stage precursors is the most reliable method to prevent CRC development. In dependence of age, familial predisposition, and other risk factors the preventative routine screening for CRC by colonoscopy should be performed at least twice in intervals of about ten years. Although colonoscopy is a life-saving clinical examination reducing both incidence and mortality of CRC significantly, it has still a bad reputation in the population as an uncomfortable procedure with unpleasant side effects lasting sometimes over days to weeks. These effects are most likely caused by the bowel preparation before colonoscopy, which is crucial for a successful colonoscopy with high quality. Beside pain, bleeding and other rare but severe complications of colonoscopy, cleaning of the intestinal mucosa alters the gut microbiome significantly and consistently. Abdominal pain, cramps, diarrhea, nausea, bloating, and constipation are common adverse events which can continue to affect patients for days or even weeks after the procedure. In this multicenter, placebo controlled, double blind clinical trial, we investigated the effect of an intervention with a multispecies probiotic formulation for 30 days on the adverse events due to bowel preparation. We show that the treatment of participants with the multispecies probiotic formulation decreases the number of days with constipation significantly, and reduced pain, bloating, diarrhea, and general discomfort. 16S based amplicon analyses reveal recovery of administered probiotic strains from stool samples and differences in alpha diversity dynamics with higher variability in the probiotic group compared to the placebo group. In conclusion, the probiotic ameliorates the side effects after colonoscopy and might be an important supplement to increase acceptance of this life-saving preventative examination. Further, we present here for the first time that probiotic intervention of only 30 days affects alpha diversity parameters in stool samples.
即使经过数十年的研究和药物研发,癌症仍是西方人群中最常见的死亡原因之一,癌症治疗仍将是医学研究的一项重大挑战。最常见的癌症类型之一是结直肠癌(CRC)。通过检测早期癌前病变进行预防是预防CRC发展的最可靠方法。根据年龄、家族易感性和其他风险因素,应至少每十年间隔进行两次通过结肠镜检查对CRC进行预防性常规筛查。尽管结肠镜检查是一种挽救生命的临床检查,可显著降低CRC的发病率和死亡率,但在人群中它仍因是一种不舒服的检查且伴有有时持续数天至数周的不良副作用而声名不佳。这些影响很可能是由结肠镜检查前的肠道准备引起的,肠道准备对于高质量的成功结肠镜检查至关重要。除了疼痛、出血和结肠镜检查的其他罕见但严重的并发症外,肠道黏膜的清洁会显著且持续地改变肠道微生物群。腹痛、痉挛、腹泻、恶心、腹胀和便秘是常见的不良事件,这些事件在检查后可能会持续影响患者数天甚至数周。在这项多中心、安慰剂对照、双盲临床试验中,我们研究了用多物种益生菌制剂进行30天干预对肠道准备所致不良事件的影响。我们发现,用多物种益生菌制剂治疗参与者可显著减少便秘天数,并减轻疼痛、腹胀、腹泻和总体不适。基于16S的扩增子分析显示,从粪便样本中可检测到施用的益生菌菌株,且益生菌组与安慰剂组相比,α多样性动态存在差异,益生菌组的变异性更高。总之,益生菌可改善结肠镜检查后的副作用,可能是提高这种挽救生命的预防性检查接受度的重要补充。此外,我们首次在此表明,仅30天的益生菌干预会影响粪便样本中的α多样性参数。